Comparison of the efficacy of two different glucocorticoid regimens for treatment of active moderate-to-severe Graves’ orbitopathy

被引：0
作者：
Mariya Asenova Stoynova
Alexander Dimitrov Shinkov
Inna Dimitrova Dimitrova
Inna Angelova Yankova
Roussanka Dimitrova Kovatcheva
机构：
[1] Medical University of Sofia,Department of Endocrinology
[2] University Hospital of Endocrinology,undefined
来源：
International Ophthalmology | 2023年 / 43卷
关键词：
Graves’ orbitopathy; Glucocorticoid regimens; Efficacy; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4747 / 4757
页数：10
相关论文
共 50 条
  • [21] Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial
    Kahaly, George J.
    Riedl, Michaela
    Koenig, Jochem
    Pitz, Susanne
    Ponto, Katharina
    Diana, Tanja
    Kampmann, Elena
    Kolbe, Elisa
    Eckstein, Anja
    Moeller, Lars C.
    Fuehrer, Dagmar
    Salvi, Mario
    Curro, Nicola
    Campi, Irene
    Covelli, Danila
    Leo, Marenza
    Marino, Michele
    Menconi, Francesca
    Marcocci, Claudio
    Bartalena, Luigi
    Perros, Petros
    Wiersinga, Wilmar M.
    LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (04) : 287 - 298
  • [22] Glucocorticoid-induced adrenal insufficiency after therapy with intravenous methylprednisolone in patients with moderate-to-severe and active Graves' orbitopathy: assessment with a low-dose corticotropin test
    Pelewicz, K.
    Miskiewicz, P.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2024, 47 (08) : 1987 - 1994
  • [23] Risk Factors for Ocular Surface Irritation Symptoms in Inactive Mild and Moderate-to-Severe Graves' Orbitopathy
    Yu, Yun
    Hu, Yu-xin
    Lu, Ming-xi
    Ouyang, Zheng-long
    Xu, Ming-tong
    Zhao, Li-yan
    Wang, Mei
    OPHTHALMOLOGY AND THERAPY, 2024, 13 (04) : 1015 - 1024
  • [24] Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe graves' orbitopathy
    Park, Jungyul
    Kim, Jaehyun
    Kim, Sang Soo
    Choi, Hee-Young
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [25] Risk Factors for Ocular Surface Irritation Symptoms in Inactive Mild and Moderate-to-Severe Graves’ Orbitopathy
    Yun Yu
    Yu-xin Hu
    Ming-xi Lu
    Zheng-long Ouyang
    Ming-tong Xu
    Li-yan Zhao
    Mei Wang
    Ophthalmology and Therapy, 2024, 13 : 1015 - 1024
  • [26] Therapy of moderate-to-severe Graves’ orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density
    Joanna Rymuza
    Michał Popow
    Zuzanna Żurecka
    Jerzy Przedlacki
    Tomasz Bednarczuk
    Piotr Miśkiewicz
    Endocrine, 2019, 64 : 308 - 315
  • [27] Therapy of moderate-to-severe Graves' orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density
    Rymuza, Joanna
    Popow, Michal
    Zurecka, Zuzanna
    Przedlacki, Jerzy
    Bednarczuk, Tomasz
    Miskiewicz, Piotr
    ENDOCRINE, 2019, 64 (02) : 308 - 315
  • [28] A pilot study on the use of prednisolone-encapsulated liposomes for the treatment of moderate-to-severe Graves' orbitopathy with reduced systemic steroid exposure
    Detiger, Sanne E.
    Kremer, Tessa M.
    A.S.H. Dalm, Virgil
    de Keizer, Ronald O. B.
    Wubbels, Rene J.
    Metselaar, J. M.
    van Hagen, P. Martin
    Peeters, Robin P.
    Paridaens, Dion
    ACTA OPHTHALMOLOGICA, 2021, 99 (07) : 797 - 804
  • [29] Efficacy of B-Cell Targeted Therapy With Rituximab in Patients With Active Moderate to Severe Graves' Orbitopathy: A Randomized Controlled Study
    Salvi, Mario
    Vannucchi, Guia
    Curro, Nicola
    Campi, Irene
    Covelli, Danila
    Dazzi, Davide
    Simonetta, Simona
    Guastella, Claudio
    Pignataro, Lorenzo
    Avignone, Sabrina
    Beck-Peccoz, Paolo
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (02) : 422 - 431
  • [30] Evaluating the safety and efficacy of baricitinib for the treatment of moderate-to-severe atopic dermatitis
    Bridgeman, Sarah G.
    Martino, Anna K.
    Strowd, Lindsay C.
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (18) : 2153 - 2159
12345